CACNB2抗体;CACNB2 Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P11617(CACNB2 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P11617(CACNB2 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The CACNB2 antibody is designed to target the β2 subunit of voltage-gated calcium channels (VGCCs), which play a critical role in regulating calcium ion influx into excitable cells, influencing processes like muscle contraction, neurotransmitter release, and gene expression. The CACNB2 gene encodes the β2 subunit, a cytoplasmic auxiliary protein essential for the trafficking, membrane localization, and functional modulation of the pore-forming α1 subunit of L-type calcium channels (CaV1.2). These channels are particularly abundant in the heart, brain, and smooth muscle.

CACNB2 antibodies are widely used in research to study the expression, distribution, and molecular interactions of the β2 subunit in physiological and pathological contexts. Dysregulation or mutations in CACNB2 have been linked to cardiovascular disorders (e.g., Brugada syndrome, arrhythmias), neurological conditions (e.g., autism, schizophrenia), and metabolic syndromes. Researchers employ these antibodies in techniques such as Western blotting, immunohistochemistry, and immunofluorescence to investigate channelopathies or assess therapeutic interventions targeting calcium signaling.

Additionally, CACNB2 antibodies aid in exploring the subunit’s role in modulating channel kinetics and its interaction with other regulatory proteins. Their application extends to drug discovery, particularly in developing treatments for hypertension, heart failure, and neurological diseases. The antibody’s specificity and validation across species (e.g., human, mouse, rat) make it a vital tool for dissecting calcium channel biology and associated diseases.